July 07, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release. Atacicept-vymj (Trutakna, Vera Therapeutics) is the first approved medication to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in immunoglobulin A (IgA)
667 words~3 min read
